Vimarsana
Biggest News Aggregation in the World

Class Approvals News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Class Approvals. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Class Approvals Today - Breaking & Trending Today

Provaris Energy Starts Hydrogen Tank Prototype Construction - Vimarsana News

Provaris Energy Starts Hydrogen Tank Prototype Construction

Provaris Energy, an Australia-based developer of green hydrogen projects, has embarked on a historic journey with the fabrication of the H2Neo prototype tank in Norway. T

Provaris taps Prodtex to build and test prototype tank for its compressed hydrogen carrier - Vimarsana News

Provaris taps Prodtex to build and test prototype tank for its compressed hydrogen carrier

Provaris has initiated a prototype tank testing program as it eyes final Class Approval for its hydrogen carrier and storage solutions.

More commercial ships utilize wind technologies to cut emissions | Hellenic Shipping News Worldwide - Vimarsana News

More commercial ships utilize wind technologies to cut emissions | Hellenic Shipping News Worldwide

Ship watchers in ports around the world are beginning to wonder: What are those funny-looking structures on the deck of some vessels? Tall columns looking like over-dimensioned funnels, or appendages reminiscent of airplane wings? They are looking at modern sails – innovative designs using the latest scientific findings to propel ships. A surprising number and ...

Global Non-Small Cell Lung Cancer Drug Forecast and Market Analysis 2019-2020 & 2029 - 29 Late-stage Pipeline Agents are Going to Enter the NSCLC Market - Vimarsana News

Global Non-Small Cell Lung Cancer Drug Forecast and Market Analysis 2019-2020 & 2029 - 29 Late-stage Pipeline Agents are Going to Enter the NSCLC Market

Share this article Share this article ResearchAndMarkets.com's offering. Non-small cell lung cancer (NSCLC) is currently the most common cancer in the world and is the leading cause of cancer mortality in men and women. Of total lung cancer incident cases, approximately 85% are the NSCLC subtype. NSCLC patients are usually diagnosed in the later stages of the disease, resulting in a poor prognosis. Since the last global market forecast (2015-2025), there have been significant changes in the treatment of patients with advanced disease, particularly in the metastatic setting. Although NSCLC i...